BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+13.22%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$25B
AUM Growth
+$25B
(+10%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
3.39%
Top 10 Holdings %
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6
Top Buys
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$437M |
| 2 |
Prelude Therapeutics
PRLD
|
$305M |
| 3 |
Kymera Therapeutics
KYMR
|
$63.3M |
| 4 |
Nurix Therapeutics
NRIX
|
$62.5M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$48.2M |
Top Sells
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$94.5M |
| 2 |
Insmed
INSM
|
$24.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
$22.1M |
| 4 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$21.6M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$21.1M |
Sector Composition
| 1 | Healthcare | 97.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Nurix Therapeutics
NRIX
$723M
| $62.5M | 0.25% |
+1,788,921
| New | +$62.5M |
|
|
ALLK
27
DELISTED
Allakos
ALLK
| $56.9M | 0.23% |
698,469
-37,000
| -5% | -$3.01M |
|
28
ADC Therapeutics
ADCT
$370M
| $55.7M | 0.22% |
1,687,500
| – | – |
|
29
Rhythm Pharmaceuticals
RYTM
$6.75B
| $53.6M | 0.21% |
2,471,155
-228,900
| -8% | -$4.96M |
|
|
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $51.8M | 0.21% |
666,500
+466,500
| +233% | +$36.2M |
|
|
GBT
31
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $50.7M | 0.2% |
920,375
+873,375
| +1,858% | +$48.2M |
|
|
ADAP
32
Adaptimmune Therapeutics
ADAP
$13.9M
| $50.5M | 0.2% |
6,330,354
-344,827
| -5% | -$2.75M |
|
|
BCEL
33
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $49.4M | 0.2% |
3,532,760
| – | – |
|
|
CCXI
34
DELISTED
ChemoCentryx, Inc.
CCXI
| $49.3M | 0.2% |
899,821
-45,400
| -5% | -$2.49M |
|
35
Neurogene
NGNE
$284M
| $45.9M | 0.18% |
3,821,740
+424,000
| +12% | +$5.09M |
|
36
BioCryst Pharmaceuticals
BCRX
$1.74B
| $43.6M | 0.17% |
12,695,818
-1,070,587
| -8% | -$3.68M |
|
37
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $42.9M | 0.17% |
2,799,577
| – | – |
|
38
Krystal Biotech
KRYS
$4.35B
| $33.4M | 0.13% |
775,192
-42,439
| -5% | -$1.83M |
|
39
Pacific Biosciences
PACB
$378M
| $32.1M | 0.13% |
+3,250,000
| New | +$32.1M |
|
40
Protagonist Therapeutics
PTGX
$3.62B
| $31.2M | 0.12% |
1,596,198
-315,248
| -16% | -$6.16M |
|
41
Spyre Therapeutics
SYRE
$1.02B
| $31.1M | 0.12% |
4,379,592
| – | – |
|
42
Altimmune
ALT
$325M
| $29.1M | 0.12% |
2,206,955
+99,355
| +5% | +$1.31M |
|
43
Apellis Pharmaceuticals
APLS
$3.51B
| $27M | 0.11% |
896,551
| – | – |
|
44
Assembly Biosciences
ASMB
$183M
| $25.3M | 0.1% |
1,541,418
-200
| -0% | -$3.16K |
|
|
DBVT
45
DBV Technologies
DBVT
$249M
| $25.3M | 0.1% |
14,614,264
| – | – |
|
46
Merus
MRUS
$5.04B
| $24.5M | 0.1% |
2,037,469
| – | – |
|
47
Aurinia Pharmaceuticals
AUPH
$1.58B
| $23.8M | 0.1% |
1,618,029
-83,900
| -5% | -$1.24M |
|
|
CBAY
48
DELISTED
Cymabay Therapeutics
CBAY
| $23.5M | 0.09% |
3,252,542
+1,729,750
| +114% | +$12.5M |
|
49
Alkermes
ALKS
$4.95B
| $22.5M | 0.09% |
1,359,001
+114,257
| +9% | +$1.89M |
|
50
Fulgent Genetics
FLGT
$674M
| $21.9M | 0.09% |
546,189
-23,255
| -4% | -$931K |
|